Mar 18, 2014 02:48 PM EDT
FDA Extends Review Process for Biogen's Multiple Sclerosis Drug, Plegridy
A new multiple sclerosis drug, Plegridy, is undergoing an extended review process. The U.S. Food and Drug Administration made the announcement earlier today, which will delay the drug’s mid-2014 release.